Shares of Immunocellular Therapeutics (IMUC) have been on the fly since the opening days of 2012, even having tripled at one point before settling down to a trading range of just below the three dollar mark.
With numerous catalysts still pending this year, including a possible move to the AMEX and the presentation of interim results for the ongoing ICT-107 trial - which could come as early as late 2012 - this is still a company and a stock to watch.
According to a press release issued by the company a couple of months ago, full enrollment for the trial is expected to reached within the current quarter and an interim analysis will be conducted "when 50% of events (32 deaths) have been observed."
Additionally, last month an announcement hit the wires that Immunocellular had established a second manufacturing site for ICT-107, which allows the company to increase production and meet the demands of the compound for the ongoing Phase II trial, but also positions the company for success should ICT-107 make it to Phase III, which looks ever more likely with each update provided by the company.
Immunocellular, as well as other developing companies in the cancer immunotherapy field, could expect to receive a speculative boost around the time of the ASCO conference, as well, which this year is scheduled for June 1-5 in Chicago.
With such catalysts pending, it's likely that IMUC could withstand any effects of a broad market sell off, were one to develop, especially with the company's technology gaining notoriety in the field of cancer immunotherapy.
Immunocellular has also spent the better part of 2012 getting the word out regarding its technology of attacking cancer cells at the stem. In continuing that pattern, Manish Singh, PhD, President and Chief Executive Officer of the Company will present at the 19th Annual Future Leaders in the Biotech Industry Conference in the Millennium Broadway Hotel & Conference Center in New York City on Friday, April 20.
Already having made 2012 a year of swift progression, this company and its stock remains one to watch.
Disclosure: Long IMUC.
Contact VFC's Stock House: vfc@vfcsstockhouse.com
Originally published at: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213